The Regulatory Leadership Briefing

Insight & News

Field notes on the rules that move markets — written by the people who do the work.

Latest EU MDR & IVDR EUDAMED: mandatory in 2026. The gap is legacy data.

The Ledger

Regulations Change.
Learn to Change With Them.

Practical guidance on the regulations reshaping your work — written to be applied, not just read.

3 articles

  1. Jul 132026
    EU MDR & IVDR

    EUDAMED Mandatory Use: The 2026 Timeline and What to Do First

    The European database has been voluntary for years. A 2025 Commission decision set the clock for mandatory use — and the work that decides whether you make it is the data you don't have yet.

    EU medical-device technical documentation review
  2. Jul 12026
    ICH Q Standards

    ICH Q12 Lifecycle Management: Are You Using It Strategically or Just Complying With It?

    Established conditions, PACMPs, and the PLCM document are levers, not paperwork. Why most manufacturers capture none of the benefit — and how to change that before your next submission.

    Technicians packaging tablets in a pharmaceutical facility
  3. Jun 302026
    EU MDR & IVDR

    Post-Market Surveillance Under EU MDR: What Device Companies Are Still Getting Wrong

    PMS remains the most common source of notified body findings, and the pattern is consistent: paperwork where a system should be. The recurring gaps, the EUDAMED clock, and how to build PMS that survives audit.

    Close-up of medical imaging equipment in a device laboratory
  4. Jun 242026
    FDA Guidance

    What FDA's 2026 Restructuring Means for Your IND Submission Timeline

    The statutory 30-day clock hasn't moved — almost everything around it has. Where a leaner, reorganized FDA actually changes your IND risk profile, and how to plan the interactions that remain.

    FDA Building 1 at the White Oak campus, Silver Spring, Maryland

One email a month. Worth opening.

New analysis and the regulatory shifts that actually matter — what we're telling clients, in one monthly briefing. No sales sequence. Unsubscribe anytime.

Work With Us

Reading Is the Cheap Part.

If an article surfaced a problem that looks like yours, bring it to us. The analysis is free — the judgment behind it is how we work. We respond within one business day, and all inquiries are strictly confidential.